Articles tagged "Drug interaction"

2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
P. A. Jacobson¹, A. Saqr¹, M. Al-Kofahi¹, D. P. Schladt², W. Guan³, W. S. Oetting¹, R. Mannon⁴, C. R. Dorr⁵, R. P. Remmel¹, G. C. Onyeaghala⁶, B. Wu³, A. K. Israni⁷, A. Matas⁸
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Hennepin Health Research Institute, Minneapolis, MN, ³Univ of MN, Biostatistics, Minneapolis, MN, ⁴Univ of Nebraska, Dept of Medicine, Omaha, NE, ⁵Hennepin Health Research Institute and Dept of Medicine, Minneapolis, MN, ⁶Hennepin Healthcare Research Institute, Minneapolis, MN, ⁷Hennepin Health Dept of Medicine and Univ of MN, Minneapolis, MN, ⁸University of MN, Dept of Surgery, Minneapolis, MN
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…
2021 American Transplant Congress
Influence of Immunosuppressive Drug Trough Levels on Nk Cells in Liver Transplantation
R. Qin¹, J. Qin², C. Sun³, B. Nashan¹
¹Clinic for Organ Transplantation, The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China, ²Clinic for Organ Transplantation, The First Affiliated Hospital of the University of Science and Technology of China., Hefei, China, ³Division of Life and Medicine, University of Science and Technology of China, Hefei, China
*Purpose: Natural killer (NK) cells are enriched in lymphocytes within the liver and are considered to be main regulators of liver transplantation (LT) rejection and…
2021 American Transplant Congress
Clazakizumab (clz, Anti-il-6 Antibody) Treatment Affects Il-6/il-6r Signaling by Increasing Soluble Gp130 (sgp130) in Hla-sensitized Kidney Transplant Patients (hs Ktx Pts) Treated for Chronic Antibody-mediated Rejection (cabmr)
B. Shin, S. Ge, A. Jimenez, N. Ammerman, A. Vo, R. Zhang, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Cerritos, CA
*Purpose: IL-6 is a pro-inflammatory cytokine responsible for chronic vascular inflammation and a promising target for cABMR modulation. IL-6/sIL-6R complex initiates more pathogenic trans-signaling pathways…
2021 American Transplant Congress
Quantifying the Interaction Between Posaconazole and Tacrolimus in Liver Transplant Recipients: A Practical Approach
B. Lane¹, U. Kaszubski¹, A. Freeman¹, B. Wise¹, L. Hutchinson¹, M. Janusek¹, G. Therapondos², H. Bohorquez³, S. Anders¹
¹Pharmacy, Ochsner Medical Center, New Orleans, LA, ²Hepatology, Ochsner Medical Center, New Orleans, LA, ³Transplant Surgery, Ochsner Medical Center, New Orleans, LA
*Purpose: The interaction between tacrolimus (FK) and posaconazole (POSA) is well documented, however the extent of this interaction and the practical management has yet to…
2021 American Transplant Congress
Implementation of a High-risk Medication Report for Waitlisted Liver Transplant Candidates
M. M. Eiting¹, H. Yeh², M. Cote¹, S. Shao¹, A. B. Scherrer², L. Dageforde², N. Elias², C. Rogers Marks¹
¹Pharmacy, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
*Purpose: Use of high-risk medications (HRMs) at the time of liver transplant may lead to delays in surgery or peri-operative complications (bleeding, drug-drug interactions (DDI),…
2021 American Transplant Congress
Pilot Evaluation of Prognosis After Liver Transplantation in Patients with a History of Hepatocellular Carcinoma and Pd-1 Inhibition
M. Chen¹, Z. Chen¹, X. Lin²
¹First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²the Eastern Hospital of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: The successful applications of programmed death protein-1 (PD-1) inhibitors in cancer therapy has led to an expanding use of immunotherapy in oncolog Liver transplantation…
2021 American Transplant Congress
A Retrospective Analysis of the Safety and Efficacy of Apixaban After Lung Transplant
T. Sam¹, K. Reininger², R. Patel¹, C. Naik¹, K. Ausloos¹, R. Rosenblatt¹, T. Grazia¹, I. Lam³
¹Transplant, Baylor University Medical Center, Dallas, TX, ²Transplant, Hennepin County Medical Center, Minneapolis, MN, ³Transplant, Sharp Memorial Hospital, San Diego, CA
*Purpose: Atrial arrhythmias and venous thromboembolism (VTE) are common after lung transplant. While direct acting oral anticoagulants (DOACs) have become anticoagulants of choice in atrial…
2021 American Transplant Congress
Management of Drug Interactions During Protocolized Implementation of Posaconazole Immediately Post Heart Transplant
G. Waldman, C. Rogers Marks, J. Clark, A. Woo, L. Irwin, A. Gerlach, G. D. Lewis, J. A. Fishman
Massachusetts General Hospital, Boston, MA
*Purpose: Posaconazole (POSA) is a strong CYP3A4 inhibitor known to increase tacrolimus exposure by up to 4-fold. Initiation requires empiric tacrolimus dose adjustment and close…
2021 American Transplant Congress
Evaluate the Effect of Cresemba (isavuconazonium Sulfate) Capsule and Noxafil (posaconazole) Delayed Release Tablets on Tacrolimus Dose to Concentration (D/C) Ratios in Lung Transplant Recipients
H. Sweiss¹, E. Kincaide¹, D. Levine², R. Hall¹
¹University Health, San Antonio, Department of Pharmacotherapy and Pharmacy Services, The University of Texas at Austin, Pharmacotherapy Division, College of Pharmacy, San Antonio, TX, ²University Health, San Antonio, University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: Evaluate the effect of Cresemba (isavuconazonium sulfate) capsule and Noxafil (posaconazole) delayed release tablet on tacrolimus dose to concentration (D/C) ratio in lung transplant.*Methods:…
2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
J. Hedvat, J. Choe, D. Salerno, J. Scheffert, D. Bley, A. Anamisis, T. Shertel, J. Lee, E. Liu, N. W. Lange
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…